Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DT3cP-Hib-MCV4 combined vaccine
- Development stage
- Unknown
- Lead developer
- CanSino Biologics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DT3cP-Hib-MCV4 is a hexavalent combination vaccine developed by **CanSino Biologics** (specifically through its subsidiary Cansino (Beijing) Biotechnology). The vaccine is designed to provide simultaneous protection against several major pediatric bacterial infections: diphtheria, tetanus, pertussis (whooping cough), *Haemophilus influenzae* type b (Hib) disease, and meningococcal disease caused by serogroups A, C, W, and Y. The pertussis component is a three-component acellular formulation (3cP), typically consisting of pertussis toxoid, filamentous hemagglutinin, and pertactin. By combining these antigens into a single injection, the vaccine aims to simplify pediatric immunization schedules and improve compliance. It is currently in Phase 1 clinical development.
- Other names
- Diphtheria, Tetanus, Pertussis (3-component acellular), Haemophilus influenzae type b, and Meningococcal (Groups A, C, W, Y) Conjugate Combined VaccineHexavalent DTaP-Hib-MCV4 Vaccine
02
Targets
FHA (Filamentous hemagglutinin)NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)PRN (Pertactin)T-cell receptor / MHC class II-presented carrier-derived peptide complexTT (Tetanus toxoid)
Beyond the preview
Go deeper on DT3cP-Hib-MCV4 combined vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DT3cP-Hib-MCV4 combined vaccine.